Merrion Pharmaceuticals Ltd., a Dublin, Ireland-based developer of oral-dosage forms of drugs with poor bioavailability, has set its IPO terms to four million American depository shares being offered at between $10 and $12 per share. It plans to trade on both the Nasdaq and IEX under ticker symbol MERR. Punk, Ziegel & Co. is serving as lead underwriter. Shareholders include Growcorp Ltd. and Elan Corp. www.merrionpharma.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.